Evidence map›Paper›PMID 27440816›Full record

ArticleJournal of clinical microbiology2016

First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America.

Fedora Lanzas, Thomas R Ioerger, Harita Shah, William Acosta, Petros C Karakousis

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fedora LanzasInstituto Conmemorativo Gorgas de Estudios de la Salud and Universidad de Panamá, Panama City, Panama.
Thomas R IoergerDepartment of Computer Science, Texas A&M University, College Station, Texas, USA.
Harita ShahDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
William AcostaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Petros C KarakousisDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA petros@jhmi.edu.

Funding

The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TBR01AI106613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2013 to 2015
$765k
NIAID NIH HHS R01 AI106613
6 · The paper itself

Abstract

The turnaround times for conventional methods used to detect Mycobacterium tuberculosis in sputum samples and to obtain drug susceptibility information are long in many developing countries, including Panama, leading to delays in appropriate treatment initiation and continued transmission in the community. We evaluated the performance of a molecular line probe assay, the Genotype MTBDRplus version 2.0 assay, in detecting M. tuberculosis complex directly in respiratory specimens from smear-positive tuberculosis cases from four different regions in Panama, as well as the most frequent mutations in genes conferring resistance to isoniazid (katG and inhA) and rifampin (rpoB). Our results were confirmed with the nitrate reductase assay and genomic sequencing. M. tuberculosis complex was detected by the Genotype MTBDRplus 2.0 assay with 100% sensitivity and specificity. The sensitivity and specificity for rifampin resistance were 100% and 100%, respectively, and those for isoniazid resistance were 90.7% and 100%. Isoniazid monoresistance was detected in 5.2% of new cases. Genotype MTBDRplus 2.0 is highly accurate in detecting M. tuberculosis complex in respiratory specimens and is able to discriminate isoniazid-monoresistant cases from multidrug-resistant cases within 2 days.

Indexed as

Drug Resistance, BacterialGenotypeAdolescentAdultAgedAged, 80 and overBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesFemaleHumansMaleMiddle AgedMolecular Diagnostic TechniquesMycobacterium tuberculosisNitrate ReductaseBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesInhA protein, MycobacteriumkatG protein, Mycobacterium tuberculosisNitrate ReductaseOxidoreductasesrpoB protein, Mycobacterium tuberculosis

Identifiers

PMID27440816
PMCPMC5035431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.